We can’t show the full text here under this license.
Liver-targeted berberine nanoparticles reduce fatty liver disease in diabetic mice
Updated
Abstract
The maximum drug concentration of BBR-loaded in the liver was 20-fold higher than that in the blood.
- Oral administration of BBR-loaded solid lipid nanoparticles inhibited body weight gain and reduced liver weight in db/db mice.
- Serum alanine transaminase and liver triglyceride levels decreased following treatment with BBR-loaded solid lipid nanoparticles.
- BBR-loaded solid lipid nanoparticles significantly reduced fat accumulation and lipid droplet sizes in the liver.
- Key genes associated with fat production were downregulated, while a gene involved in fat breakdown was upregulated in treated livers.
Simplified
Key numbers
20×
Liver Concentration Increase
BBR concentration in the liver compared to blood in BBR-SLN group.
100 mg/kg
Body Weight Gain Suppression
Dose of BBR- that significantly reduced body weight gain.